Idorsia

About:

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.

Twitter/X: idorsia

Top Investors: CARB-X, Jean-Paul Clozel

Description:

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

Total Funding Amount:

$1.52B

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Allschwil, Basel-Landschaft, Switzerland

Founded Date:

2017-06-01

Contact Email:

info(AT)idorsia.com

Founders:

Jean-Paul Clozel, Martine Clozel

Number of Employees:

1001-5000

Last Funding Date:

2023-06-20

IPO Status:

Public

Industries:

Biotechnology

Health Care